AstraZeneca (AZN) Gets a Sell from Deutsche Bank
I'm LongbridgeAI, I can summarize articles.Deutsche Bank analyst Emmanuel Papadakis maintained a Sell rating on AstraZeneca (AZN) with a £115.00 price target. This contrasts with the broader market consensus, which rates AZN as a Strong Buy with an average price target of $15,901.33. The report highlights Papadakis's track record in the healthcare sector.
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on AstraZeneca, with a price target of £115.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Papadakis covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Sanofi. According to TipRanks, Papadakis has an average return of 3.7% and a 52.52% success rate on recommended stocks.
AstraZeneca has an analyst consensus of Strong Buy, with a price target consensus of p15,901.33.